ProBiotix Health develops probiotics (live microbes that, when ingested, can alter the composition of the microbiome and improve human health) to tackle cardiovascular disease and other lifestyle conditions which are affecting growing numbers of people across the world. ProBiotix Health’s…
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon…
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for…
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company targeting the research, cultivation, manufacturing and supply of cannabinoid-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabinoid-based…
Our experienced team are here to help. Get in touch today.
General enquiries
01942 271 746
enquiries@senecapartners.co.uk
Investors & advisers
01942 295 985
clientteam@senecapartners.co.uk
Press office
0207 071 3932
zpowell@sharecomms.co.uk
Quick enquiry
Specialists in tax-advantaged investments.
Products
Resources
Policies
Copyright © 2022 Seneca Partners Limited. All rights reserved.
Seneca Partners Limited (Company No. 07196273) is Authorised and Regulated by the Financial Conduct Authority (FRN 583361).
Seneca Partners Limited’s registered office is at 9 The Parks, Haydock, WA12 0JQ.
The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.
Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.
Please confirm that you understand this warning and wish to proceed.